New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
07:43 EDTOPHTOphthotech initiates first expansion study of Fovista therapy
Ophthotech Corporation announced today the initiation of the first of several planned expansion trials, in addition to the ongoing Fovista combination therapy Phase 3 clinical program. These expansion trials will investigate the potential role of Fovista combination therapy in reducing sub-retinal fibrosis, addressing sub-optimal treatment response and reducing treatment burden in wet age-related macular degeneration patients receiving anti-vascular endothelial growth factor monotherapy. The first expansion trial is a Phase 2a open-label study investigating the potential role of anti-platelet derived growth factor therapy in combination with anti-VEGF therapy in reducing sub-retinal fibrosis in wet AMD patients. The company also announced that a subgroup analysis showing a reduction of sub-retinal fibrosis and neovascular growth in patients receiving Fovista and Lucentis in the company’s Phase 2b trial has been accepted as an oral presentation at this year’s Annual Meeting of the American Academy of Ophthalmology, one of the major medical meetings for retinal physicians.
News For OPHT From The Last 14 Days
Check below for free stories on OPHT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:32 EDTOPHTOphthotech announces Fovista Phase 2b trial presentation
Subscribe for More Information
September 9, 2014
07:55 EDTOPHTOphthotech earlier than expected Novartis payment positive, says Oppenheimer
After Ophthotech (OPHT) received a $50M Phase 3 enrollment payment from Novartis (NVS) earlier than expected, Oppenheimer thinks the payment highlights an underappreciated stock driver for Opthotech, and demonstrates that recent suggestions of Phase 3 enrollment timelines possibly slipping are unwarranted. The firm believes the company is executing well on the Fovista Phase 3 program and keeps an Outperform rating on the stock.
September 8, 2014
07:33 EDTOPHTOphthotech achieves $50M milestone under ex-agreement with Novartis for Fovista
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use